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Abstract
Background: In cell culture-based influenza vaccine production the monitoring of virus titres and
cell physiology during infection is of great importance for process characterisation and
optimisation. While conventional virus quantification methods give only virus titres in the culture
broth, data obtained by fluorescence labelling of intracellular virus proteins provide additional
information on infection dynamics. Flow cytometry represents a valuable tool to investigate the
influences of cultivation conditions and process variations on virus replication and virus yields.
Results: In this study, fluorescein-labelled monoclonal antibodies against influenza A virus matrix
protein 1 and nucleoprotein were used for monitoring the infection status of adherent Madin-
Darby canine kidney cells from bioreactor samples. Monoclonal antibody binding was shown for
influenza A virus strains of different subtypes (H1N1, H1N2, H3N8) and host specificity (human,
equine, swine). At high multiplicity of infection in a bioreactor, the onset of viral protein
accumulation in adherent cells on microcarriers was detected at about 2 to 4 h post infection by
flow cytometry. In contrast, a significant increase in titre by hemagglutination assay was detected
at the earliest 4 to 6 h post infection.
Conclusion: It is shown that flow cytometry is a sensitive and robust method for the monitoring
of viral infection in fixed cells from bioreactor samples. Therefore, it is a valuable addition to other
detection methods of influenza virus infection such as immunotitration and RNA hybridisation.
Thousands of individual cells are measured per sample. Thus, the presented method is believed to
be quite independent of the concentration of infected cells (multiplicity of infection and total cell
concentration) in bioreactors. This allows to perform detailed studies on factors relevant for
optimization of virus yields in cell cultures. The method could also be used for process
characterisation and investigations concerning reproducibility in vaccine manufacturing.
Background
Today, human influenza vaccines are still mainly pro-
duced in embryonated hen's eggs. This production system
has certain disadvantages. The amount of vaccine pro-
duced is limited to the availability of embryonated eggs,
which might be a problem in case of increased demand
for vaccination, e.g. during a pandemic [1,2]. Further-
more, the egg-based passage of virus can lead to altered
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hemagglutinin compared to the original wild-type virus,
which can have an impact on immunogenicity of the pro-
duced vaccines [3]. Currently, strong efforts are put into
the development of cell culture-based vaccine production
systems to overcome such limitations and drawbacks [1].
Several cell lines have been characterised for industrial
influenza virus production, such as Vero, the human foe-
tal retina cell line PER.C6 and Madin-Darby canine kid-
ney (MDCK) cells [4-7].
Additionally to biochemical engineering approaches,
investigation of cellular processes during viral infection is
of great importance for process optimisation. For this pur-
pose, monitoring of influenza virus production and
spread of the infection on a cellular level could provide
essential information. Furthermore, qualitative and quan-
titative monitoring of influenza virus infections is of inter-
est for in vitro studies in virological and medical research.
Monitoring of influenza virus production and spread of
the infection can also be useful for established vaccine
production processes. There, it might be used to character-
ize variations in between process batches with regard to
reproducibility and standardisation as recommended in
the process analytical technology (PAT) guidelines by the
Food and Drug Administration (FDA) [8].
Numerous methods for the assessment of influenza A
virus infection in vitro  have been established over the
years. Widespread classical methods are based on titra-
tions of virus particles in tissue-culture supernatant [9,10].
The hemagglutination assay quantifies the concentration
of infectious and non-infectious virions via binding to
erythrocytes [10,11]. In influenza virus diagnosis and
quantification in clinical samples and cell culture super-
natants, quantitative real-time PCR is widely used [12-16].
Other, more sophisticated methods for the determination
of total virus titres implement single nanometric particle
enumerators [17] or microsphere-based flow cytometric
immunoassays [18]. The concentration of infectious virus
particles is commonly determined either with a plaque
assay [19,20], or as tissue-culture infectious dose (TCID50)
[10]. Titrations of virus particles in tissue-culture superna-
tant depend on release of virus particles from infected
cells, which is a late event in the course of influenza virus
infection. The preceding stages during influenza virus
infection are virus genome replication, transcription and
translation [21,22]. The detection of viral RNA extracted
from tissue-cultures, using RNA hybridisation, is a
method for the detection of influenza virus replication
[23].
The translation of viral mRNA can be detected via immun-
ofluorescence microscopy of virus proteins. This can be
done either using polyclonal [24] or monoclonal antibod-
ies [23,25]. A comparison of the hemagglutination assay
with RNA hybridisation, titration of infectious virus and
immunofluorescence microscopy using a fluorochrome-
labelled monoclonal antibody was described by Rim-
melzwaan et al. [23]. RNA hybridisation, titration of
infectious virus and immunofluorescence microscopy
showed equal sensitivity, exceeding the sensitivity of the
HA assay.
The monitoring and quantification of host-cell infection
during cell culture-based influenza A virus production
needs to meet several goals: Preferably, it should be sensi-
tive, quantitative and robust enough to handle bioprocess
modifications such as differences in multiplicity of infec-
tion (moi) or cell concentration at time of infection. The
assay should be applicable to influenza A virus strains of
different host species to cover human and veterinary influ-
enza vaccine manufacturing. Furthermore, the assay
should allow monitoring of different virus subtypes to
comply with the annual recommendations of the World
Health Organization for human vaccines [2]. Finally, the
assay should be of use for monitoring bioprocesses with
respect to the PAT guidelines [8]. In general, bioreactor
samples are taken at different time-points during the
infection and should be measured simultaneously to
reduce preparation effort and to increase comparability
within samples. It is therefore required that the assay
allows the measurement of fixed cells. Additionally, the
staining procedure should be as rapid as possible and
allow co-staining against other physiological parameters.
For biosafety reasons and to facilitate sample handling,
virus inactivation prior to sample preparation would be
preferable. Compared to fluorescence microscopy, flow
cytometry allows acquisition of statistically reliable data
on the single-cell level with comparatively little effort and
was therefore used in this study. Additionally, the fluores-
cence distributions obtained from flow cytometry can be
used for further data analyses, such as statistical evalua-
tion of process data and mathematical modelling of virus
protein production and virion release. The transformation
of arbitrary fluorescence intensities into standardised
molecule equivalents of soluble fluorochrome (MESF)
increases the comparability of obtained result between
different experiments and cytometers [26].
The use of flow cytometry for indirect detection of virus-
infected cells with polyclonal antibodies against herpes
simplex virus type 1 (HSV-1) and influenza C virus was
presented by Steele-Mortimer et al. [27]. The method
included detection of viral infection in trypsinised non-
fixed MDCK cells combined with viability discrimination.
Lonsdale et al. [28] have reported a flow cytometric detec-
tion of infection status of Per.C6 suspension cells fixed in
paraformaldehyde (PFA) by use of fluorochrome-labelledBMC Biotechnology 2008, 8:45 http://www.biomedcentral.com/1472-6750/8/45
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murine monoclonal antibodies against viral nucleopro-
tein (NP). Until now however, no method has been
reported which covers the full range of premises for effec-
tive monitoring of cellular influenza A virus infection in
bioreactor samples as addressed above.
In the following, we present a sensitive and quantitative
method for the flow cytometric detection of influenza A
virus infection with monoclonal antibodies in adherent
MDCK cells fixed in ethanol and PFA/ethanol. This
method is based on a ready-to-use mixture of fluoro-
chrome-labelled murine monoclonal antibodies against
human influenza virus strain A (H1N1) NP and matrix
protein 1 (M1). Both M1 and NP are synthesized in the
cytoplasm of the host cells soon after infection and are
transferred into the nucleus for ribonucleoprotein packag-
ing [22]. The mixture of antibodies against M1 and NP
used in this study was not only suitable for the detection
of human influenza A (H1N1) virus proteins, but could
also be used for labelling other influenza A virus subtypes
and species. This was shown for equine (H3N8) and por-
cine (H1N2) influenza viruses, thus implying a broader
application range of the antibody mixture as reported for
the use of the antibody against NP only [23,28]. Data
obtained from infections at a high multiplicity in bioreac-
tors show the potential of this assay for monitoring virus
production processes. This also implies that the method
might be beneficial for complying with requirements of
PAT guidelines.
Results
1. Qualitative detection of different influenza A virus 
infections in MDCK cells
According to the recommendations of WHO, influenza
virus strains used for vaccine manufacturing are adapted
each year depending on the expected prevalent virus
strains. For a broad application range, detection of influ-
enza A virus strains covering a broad subtype spectrum is
desirable. In addition, detection of strains derived from
various hosts would be desirable. The antibodies used in
this study originally targeted human influenza A virus
(H1N1) M1 and NP. In order to verify if influenza virus
strains from other hosts could also be detected with these
antibodies, cells infected with equine influenza A virus
(H3N8) were analyzed by flow cytometry and laser-scan-
ning microscopy.
Laser-scanning microscopy was used for qualitative
assessment of the fluorescence-labelling of equine influ-
enza virus-infected samples (fig. 1a). Uninfected cells
were used as negative control. Microscopical images of
uninfected unstained cells (fig. 1a (I)) and uninfected
cells stained with antibodies against human influenza A
virus M1 and NP (fig. 1a (II)) did not show a difference in
fluorescence. As expected, cells infected with equine influ-
enza virus (fig. 1a (III)) showed a strong increase in green
fluorescence. The same samples were measured by flow
cytometry (fig. 1b). With flow cytometry, the unstained
uninfected cells (fig. 1b (I)) showed lower fluorescence
than the stained uninfected cells (fig. 1b (II)) while
equine influenza virus infected cells (positive control, (fig.
1b (III)) showed strong fluorescence. The fluorescence of
the unstained uninfected cells (fig. 1b (I)) was due to cel-
lular auto-fluorescence. The fluorescence increase of the
uninfected stained cells (fig. 1b (II)) compared to the
unstained cells (I) represented unspecific binding of the
antibodies to cellular components. The increase of fluo-
rescence between stained uninfected (fig. 1b (II)) and
infected (fig. 1b (III)) cells, detectable by both microscopy
and flow cytometry, was based on specific binding of at
least one of the antibodies.
The detection of influenza A virus infected cells was also
tested with cells infected by viruses of other host specifi-
city and subtype. Therefore, cells infected by human influ-
enza A virus (H1N1) and porcine influenza A virus
(H1N2) were compared to equine influenza A virus
(H3N8) infected cells (fig. 2). Cellular infection with all
influenza virus strains caused a strong increase of the flow
cytometric signal (fig. 2 (II), (III), (IV)) compared to the
stained but uninfected cells (fig. 2 (I)). The results indi-
cated specific binding of the antibodies not only to
human and equine, but also to porcine influenza A virus
proteins. Western blot analysis showed specific binding of
the antibodies against M1 and NP to human influenza M1
and NP, respectively (data not shown). Specific binding of
the anti-M1 antibody was also observed for equine influ-
enza M1. However, the anti-NP antibody showed strongly
decreased binding affinity to equine influenza NP. Thus,
the detected fluorescence signals do not necessarily reflect
binding of both antibodies in the mixture. In the follow-
ing, equine influenza virus infection was used to show
applicability of the method.
A crucial aspect, in particular for quantitative analysis, is
elimination of artefacts during preparation of control
samples for flow cytometry. Such artefacts might lead to
erroneous discrimination settings for uninfected cells. In
order to select the best negative control sample for quan-
titative analysis, cells harvested at the end of the cell
growth phase were compared to mock-infected cells.
During vaccine production in MDCK cells, serum-con-
taining cell growth medium is replaced by serum-free
virus maintenance medium with intermediate washing
steps prior to influenza virus infection. The influence of
these changes in culture conditions on unspecific anti-
body binding in uninfected cells was investigated. Mock-
infection simulated the procedure during the preparation
for viral infection (without adding the virus seed), thusBMC Biotechnology 2008, 8:45 http://www.biomedcentral.com/1472-6750/8/45
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Detection of equine influenza A virus infection in MDCK cells Figure 1
Detection of equine influenza A virus infection in MDCK cells. 1a: Fluorescence microscopy (LSM510, Zeiss: 400×, 
excitation: 488 nm, emission: 520–530 nm); 1b: flow cytometry. Uninfected cells: unstained (I) and stained against influenza A 
virus M1 and NP (II); infected cells: equine influenza A virus-infected, 18 h p.i., stained against influenza A virus M1 and NP (III).BMC Biotechnology 2008, 8:45 http://www.biomedcentral.com/1472-6750/8/45
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representing the treatment of infected cells more precisely
than the use of cells harvested from growth medium. Two
types of negative control were used: uninfected cells har-
vested from cultivation in cell growth medium (CGM)
without medium exchange (see also fig. 2, (I)) and mock-
infected cells (see above). Flow cytometric analysis
revealed an increase in green fluorescence in mock-
infected cultures (fig. 3, (II)) compared to uninfected cells
(fig. 3 (I)). Hence, the washing procedure and medium
change from CGM to virus maintenance medium (VMM)
led to an increase in unspecific fluorescence independent
of viral infection (table 1). Compared to mock-infection,
the use of uninfected cells harvested from cell growth
medium as negative control would have introduced an
undesired underestimation of unspecific antibody bind-
ing leading to an overestimation in the quantification of
infected cells. Therefore, mock-infected samples were
used as negative controls in all further experiments.
Another aspect examined was the dependence of the
immunofluorescence on the time of harvest post infec-
tion. In order to asses this, MDCK cells were infected with
equine influenza virus at a moi of 1.0 and harvested 6 h
p.i. and 18 h p.i., respectively. These cells were measured
flow cytometrically (fig 3). Compared to cells harvested 6
h p.i. (fig. 3 (IV)), cells harvested 18 h p.i. (fig. 3 (III))
showed a reduced mean fluorescence intensity. Further-
more, their fluorescence distribution was broader. The dif-
ferences in measured fluorescence intensity indicated
changes of intracellular influenza A virus M1 and NP con-
tent during the course of infection. The choice of the cell
fixative depends on the cellular feature being investigated
[29].
Fixation and storage in ethanol was reported to be suita-
ble for long-term conservation [30], which is beneficial
for the intended application. The influence of ethanol fix-
ation on the stainability was therefore compared to PFA
fixation with subsequent ethanol fixation to investigate
which fixation procedure yields better results (data not
shown). Ethanol fixation led to a decrease in unspecific
immunostaining with mock-infected cells and an increase
in specific immunofluorescence of equine influenza virus-
infected cells compared to PFA/ethanol fixation. Thus, as
Infection of MDCK cells by different influenza A virus strains Figure 2
Infection of MDCK cells by different influenza A virus 
strains. Immunocytometric detection of cells stained with 
antibodies against influenza A virus M1 and NP. (I): unin-
fected cells; (II): cells infected with equine influenza A virus 
H3N8 (18 h p.i.); (III): cells infected with porcine influenza A 
virus H1N5 (18 h p.i.); (IV): cells infected with human influ-
enza A virus H1N1 (18 h p.i.).
Table 1: Quantification of flow cytometric measurements (n = 5; 
1.0*104 cells per sample).
uninfected mock-infected Infected
mean im 13.0 18.2 261.7
mean cMEF 4.19 *104 5.98 *104 9.02 *105
RSD of mean cMEF ± 8.45 ± 2.46 ± 1.66
ci 0.0 8.42 *105
im = fluorescence intensity measured by flow cytometry
cMEF = number of MEF per cell, according to calibration of 
fluorescence with Sphero
FITC Calibration particles (eq. 1, fig. 5)
ci = number of MEF per cell bound specifically to virus proteins in cells 
(eq. 2)
Influence of time of harvest on negative controls and infected  cells Figure 3
Influence of time of harvest on negative controls and 
infected cells. Immunocytometric detection MDCK cells 
stained with antibodies against influenza A virus M1 and NP: 
Negative controls: uninfected cells (I), mock-infected stained 
cells, harvested 2 h p.i. (II); infected cells: equine influenza A 
virus-infected, harvested 18 h p.i. (III), equine influenza A 
virus-infected, harvested 6 h p.i. (IV).BMC Biotechnology 2008, 8:45 http://www.biomedcentral.com/1472-6750/8/45
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the choice of the fixation method was not restricted by fix-
ation requirements of additional staining, ethanol fixa-
tion was favoured over PFA/ethanol fixation. Both
fixation methods were found to inactivate infectious sam-
ples, which facilitated the handling of virus material.
2. Quantitative detection of equine influenza A virus 
infection in MDCK cells
The fluorescence distributions measured by flow cytome-
try were used to quantify the status of infection (i.e., to
distinguish between infected and uninfected cells). Culti-
vation conditions preceding infection (washing steps,
medium exchange) also had an impact on unspecific cell
fluorescence, as shown by differences in fluorescence of
uninfected compared to mock-infected cells (see fig. 3,
and table 1). Mock-infected cells reproduced unspecific
fluorescence changes occurring in infected cell cultures
better than uninfected cells and were therefore used as
negative controls. Cells with fluorescence higher than
99% of the mock-infected cells were defined as infected.
Correspondingly, the fluorescence threshold for the detec-
tion of an infected cell was set equal to the quantile (mean
x0.99) of the cumulative fluorescence distribution (F) of
mock infected cells. The fluorescence intensity at x0.99 did
not only depend on the mean fluorescence intensity of the
mock-infected cells (mean im) but also on the correspond-
ing fluorescence distribution width.
In order to compare measured fluorescence intensities of
cell populations, a fluorescence calibration was done
using Sphero FITC Calibration particles (fig 4). Accord-
ingly, the fluorescence intensities could be transformed to
numbers of molecules of equivalent fluorescein. This
standardisation allows comparisons of signal intensities
not only within samples stained in a group but also
within different staining groups, e.g. measurements of dif-
ferent bioprocess batches. The difference in the molar
quantum yield between fluorescein conjugated to calibra-
tion particles and to antibody molecules was not taken
into account. Thus, the fluorescence from antibody bind-
ing measured by flow cytometry was expressed as mole-
cules of equivalent fluorescein (MEF) as calibrated with
fluorescent particles. The number of MEF per cell cMESF
was calculated from the measured fluorescence intensity
(im) taking into account the slope of the calibration curve
(eq. 1).
cMEF = 3457.1 · im - 3161 (1)
The fluorescence threshold of samples taken at time of
infection (t = 0 h) was used to determine the number of
MEF bound unspecifically to cells (cMEF,t = 0). The number
of MEF bound specifically to virus proteins of an infected
host cell (ci) was calculated by subtracting the number of
unspecifically bound MEF (cMEF,t = 0) from the measured
total number of MEF per cell (cMEF,i, eq. 2).
ci = cMEF,i - cMEF,t = 0 (2)
Mock-infected cells were stained and analysed to detect
the increase in background fluorescence at time of infec-
tion (toi) caused by washing steps and medium exchange
(table 1). Equine influenza virus-infected cells (harvested
18 h p.i.) were stained and analysed. The number of MEF
specifically bound per cell was calculated by subtracting
the calculated mean MEF in mock-infected cells from the
mean MEF in infected cells. The average number of MEF
per cell was 8.42*105 in equine influenza virus-infected
cells harvested 18 h post infection.
To characterize the time course of the fraction of infected
cells in a single-step infection experiment, MDCK cells
were infected with equine influenza virus at a moi of 3.0
(fig. 5). The cells were cultivated on microcarriers in a lab-
scale bioreactor (1 l working volume). Cells harvested at
time of infection were used as negative controls for the
determination of the fluorescence threshold. For the
quantification of the fraction of infected cells at x0.99 a
minimum signal intensity (cMEF) of 3.58*105 MEF was
necessary. Between 2 to 4 h p.i. the mean cMEF of all
measured cells increased, indicating the onset of intracel-
lular accumulation of synthesized virus proteins. Most of
the expected fraction of infected cells (close to 100% of all
cells) could be detected at 6 h post infection. Thus, this
was considered the earliest time-point of quantification of
cellular infection. The percentage of infected cells
Fluorescence intensity calibration Figure 4
Fluorescence intensity calibration. Flow cytometric 
measurement of Sphero FITC Calibration particles (–: linear 
display after logarithmic data acquisition). For each particle 
population the mean fluorescence intensity was calculated 
from three samples (mean of im: ∆ ± S.D.), fitted by linear 
regression (---).BMC Biotechnology 2008, 8:45 http://www.biomedcentral.com/1472-6750/8/45
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remained relatively constant (mean: 90.0% ± 4.9%) up to
22 h p.i. and quite unaffected by changes of the mean flu-
orescence, especially between 16 to 22 h post infection.
During this time the measured fluorescence intensities
showed large variations (mean cMEF: 2.18*106 ± 41.9%),
probably indicating variations in virus protein content per
cell over time of infection.
3. Vaccine production process monitoring: infection status 
of cells and virus titres
Commonly, virus titrations using hemagglutination,
plaque formation or immunostaining are used to quantify
the concentration of virus particles in cell culture superna-
tants during vaccine production. Infectious and non-
infectious influenza virions are released by budding from
the apical surface of their host cells, which is preceded by
viral genome replication and intracellular virus protein
accumulation. For a comparison of the flow cytometric
detection of cellular infection status with standard titra-
tion methods, MDCK cells were cultivated on microcarri-
ers in a lab-scale bioreactor (1 l wv). The cells were washed
and infected with equine influenza A virus (H3N8) at a
moi of 3. The time course of the cellular infection status is
shown in fig. 5. Additionally to flow cytometry, the
progress of virus infection was monitored by analysis of
extracellular virus particle production. Total and infec-
tious virus particle release into the culture supernatant
was analysed with hemagglutination (fig. 6a) and TCID50
assay (fig. 6b), respectively. The comparatively high viral
titres at the beginning of infection reflect the high moi
used for this cultivation. The concentration of total virus
particles increased over time from 0.9 log HA units/100 µl
to a maximum of 2.1 log HA units/100 µl at 22 h post
infection. Correspondingly, the concentration of infec-
tious viruses increased from 1.3 *106 to 1.8 *107 virions/
ml with an intermediate decrease to 5.6 *106 virions/ml
between 16 and 22 hours.
The onset of intracellular virus production could be
detected by an increase in the fluorescence (ci) at 4 h p.i.
(fig. 5). At this time point about 60% of the cultured cells
were clearly infected, whereas no increase in total virus
particle number in the supernatant was detected via the
HA assay (fig 6a).
Between 4 to 6 h p.i., the first virus particles were released
from infected cells, as measured by the increase in HA and
TCID50. At 6 h p.i., the percentage of infected cells was
already close to its maximum, while a first maximum in
the cellular fluorescence was reached at about 10 h p.i.
(fig. 5). Obviously, the onset of virus particle release
already took place prior to the maximum accumulation of
viral antigen molecules in the host cells. Thus, the fluores-
cence intensity represents a net result of intracellular virus
protein production and release of virus particles.
The increase in cellular fluorescence at 16 h p.i. and its
decrease at 20 h p.i. was possibly caused by a population
of cells infected during a second infection step at a later
time-point, despite the comparatively high moi of 3 used
in this study. This could also be concluded from the
increase in infectious and total viral titres 20 h post infec-
tion.
Discussion
We tested a ready-to-use fluorochrome-labelled mono-
clonal antibody mixture for the detection and monitoring
of influenza A virus infection in fixed MDCK cells. The
results from fluorescence microscopy and flow cytometry
indicated that the combination of antibodies used is suit-
able not only human influenza A strains, but also for the
detection of equine and porcine influenza A virus infec-
tion in cultured adherent MDCK cells. Furthermore, it was
demonstrated that the assay is applicable to virus strains
of different subtypes (human: H1N1, equine: H3N8 and
porcine: H1N2). This indicated that the antibody mixture
could be used for an even broader range of virus strains
and host species origins than previously reported for the
antibody against NP only [28].
The method was shown to be suitable for the measure-
ment of fixed samples taken at different time-points dur-
ing an experiment (e.g., bioreactor cultivations (fig. 5)).
In contrast to the measurement of unfixed cells as
reported by Steele-Mortimer et al. [27], it was possible to
Quantitative detection of equine influenza A virus infection Figure 5
Quantitative detection of equine influenza A virus 
infection. Cellular infection status (■ ) and measured fluo-
rescence intensity during infection of MDCK cells with 
equine influenza virus in a lab-scale bioreactor (1 l wv, moi = 
3.0); duplicate measurements (symbols) and profile of the 
corresponding mean (lines).BMC Biotechnology 2008, 8:45 http://www.biomedcentral.com/1472-6750/8/45
Page 8 of 12
(page number not for citation purposes)
collect samples and stain them simultaneously to reduce
sample preparation effort. Furthermore, both ethanol and
PFA/ethanol fixation resulted in virus inactivation of the
samples (data not shown). This effect led to increased
biosafety and facilitated handling during sample prepara-
tion for flow cytometry.
The measured fluorescence from samples of equine influ-
enza virus-infected cultures taken at different time-points
suggests a time-dependent behaviour of the immunofluo-
rescence signal (fig. 3). This is most likely due to the pro-
duction and release kinetics of viral proteins of infected
cells [22,28,31].
The earliest time-point of detection of virus protein accu-
mulation was between 2 to 4 h p.i., which is consistent
with the findings for the microscopic analysis using an
antibody against influenza A virus NP only [23]. Com-
pared to fluorescence microscopy, flow cytometry facili-
tates monitoring of thousands of cells, providing
extensive data sets for mathematical analysis of virus
dynamics with regard to spreading of the infection in cell
populations. A calibration of arbitrary fluorescence inten-
sities in terms of MEF increases the comparability of dif-
ferent experiments. Quantification of the fraction of
infected cells was possible at about 6 h post infection,
which is in good agreement with Lonsdale et al. [28], who
have shown the quantification of human influenza A
virus infection in PFA-fixed PER.C6 suspension cells at 5
h post infection.
In comparison with two titration methods routinely used
in vaccine manufacturing, flow cytometry could detect
viral infection at an earlier stage (fig. 5 and fig. 6). How-
ever, moi used in vaccine production is usually much
lower to reach optimal product yields. Most likely, the
advantage of flow cytometric monitoring would be even
bigger as accumulation of virus proteins in individual
cells could be detected long before significant amounts of
virus particles are released for titration assays (the detec-
tion limit of the hemagglutination assay is about 2.0 *107
virions/ml).
After 6 h p.i. the fraction of infected cells, calculated from
cytometric measurements, appeared to be stable, despite
changes in the fluorescence intensity that occurred during
the following infection phase (fig. 5). An underlying
mechanism for these changes might be an initial intracel-
lular accumulation of produced virus proteins followed
by packaging and release of viral particles starting at a later
stage of viral replication. This is supported by the fact that
virus release, monitored by HA and the TCID50 assay, was
not detected before 4 to 6 h p.i. (fig. 6a and 6b), whereas
intracellular virus protein synthesis was detected already
at 2 to 4 h p.i. by flow cytometry (fig. 5). Accordingly, the
measured fluorescence intensities per cell appear to dis-
play the net result of intracellular virus protein accumula-
Comparison of standard titration methods with flow cytometry for monitoring virus infection Figure 6
Comparison of standard titration methods with flow cytometry for monitoring virus infection. Equine influenza 
virus infection of MDCK cells in a lab-scale bioreactor (1 l wv, moi = 3.0, last sample not analyzed by flow cytometry due to cell 
lysis); 6a: total virus particle concentration measured by hemagglutination assay ( ± standard error of the method); 6b: infec-
tious virus concentration determined via virus infectivity assay (TCID50, • ± standard error of the method).BMC Biotechnology 2008, 8:45 http://www.biomedcentral.com/1472-6750/8/45
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tion and release via virus budding. An alternative
explanation might be that the moi of 3 used to initiate this
single-step infection experiment was not sufficient to
infect all cells simultaneously. Consequently, a certain
percentage of cells could have started to release virions
with a delay resulting in a similar time course in HA and
TCID50 titres. Additional experiments are currently being
performed to elucidate this finding.
Conclusion
In conclusion, flow cytometric monitoring of influenza A
virus infection in adherent MDCK host cells using a ready-
to-use mixture of antibodies against influenza A NP and
M1 is applicable to a broader range of virus strains than
previously reported. Due to its sensitivity and its robust-
ness to process modifications – such as seed virus (host
specificity and subtype), multiplicity of infection and cell
concentrations – flow cytometry is a useful addition to
standard titration methods for the monitoring of influ-
enza A virus replication. Furthermore, it allows the gener-
ation of large data sets for statistical process analysis and
validation of mathematical models for virus dynamics.
The application of this monitoring method in vaccine
manufacturing may give new insights on virus infection
dynamics supporting process development and optimiza-
tion. For example, characterisation of the influence of moi
on virus spreading and virus yields for different virus sub-
types. In established processes, the method could be used
for process analysis according to the PAT initiative to com-
plement analysis of production runs, to facilitate interpre-
tation of the impact of process variations on product
quality or to support measures for improving batch to
batch reproducibility.
Methods
Cell line
Madin-Darby canine kidney cells were obtained from
ECACC (No. 84121903) and used for viral infection stud-
ies as described previously [7]. The adherent cells were
expanded in cell growth medium (CGM): GMEM supple-
mented with 10% FCS (Gibco #10270-106) and 2 g/L
peptone (International Diagnostics Group #MC33) in T-
flasks and small-scale microcarrier cultures (Cytodex 1,
GE Healthcare).
Viruses
Equine influenza strain A/Equine 2 (H3N8)/Newmarket/
1/93 (NIBSC), human influenza strain A (H1N1)/Puerto
Rico/8/34 (NIBSC) and porcine influenza A/Swine
(H1N2)/Bakum 1832/00 ([32,33]; seed virus was a kind
donation from B. Hundt, Impfstoffwerke Dessau-Tornau)
were used to infect MDCK cell cultures. After cell expan-
sion in CGM the cultured cells were washed with phos-
phate-buffered saline (PBS) and further cultivated in FCS-
free virus maintenance medium (VMM) containing 1 mg/
l porcine trypsin (Gibco #27250-018) as described previ-
ously [7]. Mock-infected cultures were treated like
infected cultures but without addition of seed virus.
Preparation of standard samples
Uninfected MDCK cells from tissue flasks were harvested
and fixed after four days of cultivation in CGM (negative
control). Mock-infected MDCK cells were cultivated
accordingly, harvested and fixed 1 h after the medium
exchange (mock-infected negative control).
For positive controls, MDCK cells infected after 4 days
(moi = 1.0) were used. Equine and human influenza A
virus infected cells were harvested 18.0 h post infection
(p.i.), whereas porcine influenza A virus infected cells
were harvested 24.3 h post infection. All standard samples
were stored in aliquots at -20°C until further analysis.
Bioreactor cultivation
Small-scale bioreactor cultivations of MDCK cells were
performed in a bioreactor (1 L wv) equipped with a glass
ball agitator (DasGip). Cytodex 1 microcarriers were used
at a concentration of 2 g/l (about 8 000 particles/ml).
After a cell growth phase of 95 h the cells were washed
with PBS and CGM was replaced by the same volume of
VMM. Then the cells were infected with equine influenza
virus (moi = 3.0).
Hemagglutination assay
Titration of total viral particles was based on the method
by Mahy and Kangro [10] with modifications described
by Genzel et al. [7]. Titres are reported as log HA units per
test volume (100 µl). Total virus particle concentrations
were calculated from HA units, assuming that at the last
dilution of virus showing complete agglutination, the
ratio of red blood cells (RBC) and virus particles is equiv-
alent (1) [9]. The concentration of red blood cells (cRBC)
per ml test volume was kept constant (1*107 RBC/ml) for
all measurements (eq.3).
total virus particle concentration = cRBC * 10(log HA titre/100 
µl) (3)
The lower detection limit of the assay was 2.0*107 virus
particles/ml. Due to a 2n dilution of samples the standard
error of the method was ± log 0.3.
Virus infectivity assay
Infectious virus particle concentrations were determined
as tissue-culture infectious dose (TCID50) titrations based
on [10] with previously described modifications [34]. The
quantification limit was 3.2*102 infectious virus particles/
ml with a standard error of the method of ± log 0.3 due to
2n dilution of samples.BMC Biotechnology 2008, 8:45 http://www.biomedcentral.com/1472-6750/8/45
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Cell harvest and sample storage
Cells from both tissue-culture flasks and microcarrier cul-
tures were harvested for immunostaining of influenza
virus infection.
Supernatants of tissue-culture flasks were centrifuged (60
g, 20 min, 4°C) to concentrate floating cells in a reduced
volume. Adherent cells were washed with PBS and
detached by trypsin/EDTA treatment (0.05% w/v trypsin,
0.02% w/v EDTA in PBS) at 37°C. Subsequently,
detached cells and cells from supernatant were pooled.
Samples from microcarrier cultivations were separated
into two fractions by sedimentation of the microcarriers.
The culture supernatants were centrifuged to concentrate
floating cells as described for tissue-culture flask superna-
tants. The settled microcarriers were washed with PBS. In
a subsequent step the adherent cells were detached from
the microcarriers with trypsin/EDTA (0.5% w/v trypsin,
0.02% w/v EDTA in PBS). After cell detachment, the cells
from culture supernatants were added again. Cells were
separated from the empty microcarriers by sedimentation
of the microcarriers.
From these pooled cell suspensions, 1.0*106 cells per aliq-
uot were fixed in ethanol (70% v/v, -20°C) and stored at
-20°C for at least 2 h. Infectious virus particles were inac-
tivated by ethanol fixation (data not shown). For addi-
tional PFA fixation, the cells were kept in PFA (Sigma,
#158127, 1% final concentration in PBS) for 20 min at
room temperature. Afterwards, the samples were centri-
fuged (60 g, 20 min, 4°C) and washed once with PBS
prior to ethanol fixation as described above.
Immunostaining against influenza A virus M1 and NP
For the detection of influenza A virus infection, a mixture
of murine monoclonal antibodies was used [35]. The
ready-to-use antibody mixture (IMAGEN™ Influenza virus
A and B, reagent A, DakoCytomation, # K6105) contained
fluorescein-conjugated monoclonal antibodies (FITC-
MAbs) against human influenza A virus NP and M1 at a
concentration of 25 µg/ml each.
Ethanol-fixed aliquots of suspended cells were centrifuged
at 100 g for 20 min at 4°C. The supernatant was discarded
and the pellet was washed with 5 ml PBS containing gly-
cine (2% w/v) and BSA (0.1% w/v). Subsequently, the
samples were centrifuged at 100 g for 30 min at 4°C. The
pellet was resuspended in 2 ml PBS with glycine and BSA,
transferred into 2 ml reaction tubes and centrifuged at 60
g for 15 min at 4°C. After removal of the supernatant the
pellet was dissolved in 25 µl of the FITC-MAb solution
and incubated for 1 h in the dark at 37°C on a tube roller.
Following the incubation, unbound antibody was
removed by addition of 1.8 ml PBS and subsequent cen-
trifugation (60 g, 15 min, 4°C). Finally, the pellet was
resuspended in 0.5 ml PBS for flow cytometry or in 0.1 ml
PBS for immunofluorescence microscopy, respectively.
The samples were stored in the dark at room temperature
until analysis.
DNA content measurement for cell cycle analysis
In addition to immunostaining, the cell cycle distribution
was determined via DNA content in bioreactor samples
(data not shown). DNA content measurements were per-
formed as previously described [36]. Briefly, ethanol-fixed
cells were prepared for DNA content measurements
according to [30] with the following modifications: cen-
trifugation steps were carried out with 100 g for 20 min at
4°C to minimize cell loss, and propidium iodide (Sigma,
# P4170) staining and RNA digestion was performed at
37°C for 40 min prior to subsequent flow cytometry.
Calibration of molecules of equivalent fluorescein (MEF) 
from fluorescence intensity
Measured fluorescence intensities were standardised using
a fluorescein-specific fluorescence calibration kit (Sphero
FITC Calibration Kit, Spherotech, # ECFP-F1-5K). MEF
values of the calibration beads were determined in com-
parison to fluorescein-conjugated beads (NIST) by the
supplier. Accordingly, the MEF values were taken from the
supplier's certificate of analysis. The calibration beads
were diluted in PBS in order to avoid pH-based differences
in fluorescence per fluorescein molecule between calibra-
tion and sample measurements [37]. The mean fluores-
cence intensity (MFI) was calculated from three
measurements. The calibration curve resulting from linear
regression of mean channel number versus MEF values of
the corresponding beads resulted in a slope of MEF per
fluorescence channel (see Results, chapter 2.: Quantitative
detection of equine influenza A virus infection in MDCK
cells). The labelling efficiency of the antibodies was 2.3
fluorescein molecules per antibody molecule as specified
by the supplier.
Flow cytometry
Cytometric measurements were performed with a Beck-
man Coulter Epics XL cytometer (Beckman Coulter)
equipped with a 488 nm argon laser using the Expo32
software (Beckman Coulter). Two aliquots of each sample
were stained and 1.0 * 104 single cells analyzed. Cells were
distinguished from debris via forward-light scattering
(FSC) and side-light scattering (SSC). Single cells were dis-
criminated from cell aggregates using plots of forward-
light scattering signal area (FSC-A) against forward-light
scattering signal height (FSC-H). FITC fluorescence acqui-
sition was performed with logarithmic binning.
Cells of bioreactor samples were stained with both pro-
pidium iodide and FITC-MAbs. Here, cell aggregates wereBMC Biotechnology 2008, 8:45 http://www.biomedcentral.com/1472-6750/8/45
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distinguished from single cells via the signal ratio of red
fluorescence signal area and signal peak.
For the discrimination between infected and uninfected
cells mock-infected negative control samples were stained
and analyzed. The fluorescence intensity border between
infected and uninfected cells was set to a quantile (mean
x0.99) of the cumulative distribution (F). Mean x0.99 was
determined from two measurements of an immunos-
tained negative control, using mock-infected or infected
cells (harvested 0 h p.i.), respectively.
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